Core Insights - Investors are taking a bearish stance on AbbVie, with significant options activity indicating potential insider knowledge of upcoming events [1][2] - The overall sentiment among large investors is slightly bearish, with 54% bearish and 45% bullish positions [2] - Significant investors are targeting a price range of $160.0 to $220.0 for AbbVie over the past three months [3] Options Activity - In the last 30 days, 11 uncommon options trades were identified for AbbVie, with 9 puts totaling $807,896 and 2 calls totaling $67,330 [2][4] - Detailed analysis of options activity shows a focus on bearish trades, with notable put options indicating a lack of confidence in the stock's near-term performance [9] Company Overview - AbbVie is a pharmaceutical company with strong exposure to immunology and oncology, having expanded its portfolio through acquisitions, including Allergan in 2020 and recent acquisitions in neuroscience and oncology [10] - Analysts have provided a range of target prices for AbbVie, with an average target of $247.4, and individual targets ranging from $222 to $270 [12][13] Market Performance - AbbVie’s current trading volume stands at 2,435,721, with the stock price at $220.44, reflecting a 0.87% increase [15] - The stock may be approaching overbought conditions, with an earnings announcement expected in 33 days [15]

Key Takeaways AbbVie projects revenue growth in 2025 despite Humira sales falling by over 54% in the first half of 2025.Skyrizi and Rinvoq are fueling gains with new launches, head-to-head data and expanding indications.AbbVie is also expanding in oncology and neuroscience, adding new drugs and boosting migraine uptake.AbbVie (ABBV) expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent i ...

Accessibility StatementSkip Navigation The majority of adverse events were non-serious and mild or moderate in severity across TEMPO-1 through 3. The incidence of SAEs and deaths were low and comparable between placebo and tavapadon groups. The most common adverse reactions reported in 10% of patients were nausea, headache and dizziness for Parkinson's disease patients without levodopa, and nausea and dyskinesia for patients on adjunctive therapy with levodopa. NORTH CHICAGO, Ill., Sept. 26, 2025 /PRNewswir ...

EXTON, PA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Rheumatologists report high satisfaction with AbbVie’s Rinvoq (upadacitinib) following its recent approval in giant cell arteritis (GCA), with the majority citing anticipated efficacy, steroid-sparing benefits, and convenient oral administration as central drivers of adoption. Nearly all specialists are aware of the approval, and 40% have already prescribed Rinvoq for GCA patients, an early adoption curve that compares favorably with the brand’s prior launches i ...

Accessibility StatementSkip Navigation Allergan Aesthetics Global Medical Affairs Symposium on Skin Quality Multimodal MasteryA single- strategy treatment plan may not be enough to unlock the skin's full potential, and a multimodal approach is the focus of this year's medical symposium, 'Mastering Skin Quality - Integrating Aesthetic Modalities for Holistic Skin Quality Improvement' on Wednesday, 1 October at 2PM-4PM in Al Ameera Ballroom 2, Grand Hyatt Dubai. With 94% of people wanting to improve their fa ...

Company Performance - AbbVie closed at $219.99, reflecting a -1.18% change from the previous day, underperforming the S&P 500's loss of 0.29% [1] - Over the past month, AbbVie shares gained 6.84%, outperforming the Medical sector's loss of 0.33% and the S&P 500's gain of 3.08% [1] Upcoming Earnings - AbbVie's upcoming earnings per share (EPS) are projected to be $3.26, indicating an 8.67% increase from the same quarter last year [2] - Revenue is estimated at $15.54 billion, reflecting a 7.5% rise from the equivalent quarter last year [2] Full Year Projections - For the full year, earnings are projected at $12.02 per share and revenue at $60.64 billion, representing changes of +18.77% and +7.64% from the prior year [3] - Recent adjustments to analyst estimates indicate evolving short-term business trends, with positive revisions suggesting analyst optimism [3] Zacks Rank and Valuation - AbbVie currently holds a Zacks Rank of 3 (Hold), with a Forward P/E ratio of 18.53, which is a premium compared to the industry average of 14.34 [5] - The PEG ratio for AbbVie is 1.33, compared to the Large Cap Pharmaceuticals industry average of 1.53 [6] Industry Overview - The Large Cap Pharmaceuticals industry is part of the Medical sector and holds a Zacks Industry Rank of 106, placing it in the top 43% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1 - The Dividend Kings achieved a gain of 3.26% in August, outperforming the SPDR S&P 500 ETF Trust (SPY) by 1.21% [1] - In September, SPY has increased by 2.9% [1]

Licensing Deal - Glenmark Pharmaceuticals Ltd announced a licensing deal with Chinese drugmaker Hengrui Pharma for its under-development lung and breast cancer drug, Trastuzumab Rezetecan (SHR-A1811) [1][2] - The deal includes an upfront payment of $18 million, regulatory and commercial milestone payments of up to $1.093 billion, and royalties based on net sales within the licensed territory [1][4] Drug Details - Trastuzumab Rezetecan is a next-generation antibody drug conjugate (ADC) targeting HER2-positive cancers, combining an antibody with a chemotherapy drug to deliver treatment directly to cancer cells [2] - The drug was approved in China in May 2025 for treating adult patients with non-small cell lung cancer that is either inoperable or metastatic [3] Clinical Development - Trastuzumab Rezetecan is currently advancing multiple clinical trials and received Orphan Drug Designation from the US FDA in August 2025 for gastric or gastroesophageal junction adenocarcinoma [3] Market Strategy - Under the licensing agreement, Glenmark can develop and commercialize the drug in emerging markets, excluding major regions like China, the US, Canada, Europe, Japan, Russia, and the CIS [4] - The company aims to expand its oncology pipeline and leadership, focusing on delivering next-generation therapies in underserved markets [5] Recent Collaborations - In May 2024, Glenmark entered an agreement with BeOne to market and distribute cancer medicines Tislelizumab and Zanubrutinib in India [6] - In July 2025, Glenmark's US-based unit licensed a blood cancer drug to AbbVie Inc. for $700 million, marking a significant outlicensing deal for Indian drugmakers [6][7] Financial Performance - Glenmark's share price closed 0.2% higher at ₹2,020.10 on the National Stock Exchange following the announcement of the licensing deal [8]

智通财经APP获悉，9月23日，药品审评中心(CDE)网站显示，艾伯维(ABBV.US)的艾可瑞妥单抗注射液(epcoritamab)在华申报新适应症。根据优先审评进 展，本次申报的适应症为联合利妥昔单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤(FL)成人患者。 艾可瑞妥单抗是Genmab利用其专有的DuoBody技术开发的一款IgG1双特异性抗体，可同时靶向T细胞上的CD3和B细胞上的CD20，诱导T细胞杀伤 CD20+细胞。 8月7日， 一项评估艾可瑞妥单抗联合利妥昔单抗+来那度胺对比利妥昔单抗+来那度胺方案，用于成人复发或难治性滤泡性淋巴瘤(R/R FL)患者的疗效与 安全性的III期研究(EPCORE FL-1研究)取得积极结果。预设中期分析显示，该研究已达到ORR和PFS双重主要终点。 艾可瑞妥单抗联合治疗组的ORR达95.7%(p<0.0001)，PFS风险比(HR)为0.21(p<0.0001)，疾病进展或死亡风险降低79%。美国FDA已受理艾可瑞妥单抗用于 该适应症的sBLA并授予优先审评资格，PDUFA日期为2025年11月30 日。 | 受理品种目录浏览 | 在审品种目录浏览 | | | | ...

Core Insights - Allergan Aesthetics is expanding the rollout of SKINVIVE by JUVÉDERM to 35 additional markets, bringing the total to 57 globally in 2025, highlighting the company's commitment to enhancing skin quality worldwide [1][5][9] - The global skin quality market is valued at $5.2 billion, with a notable shift in consumer behavior towards health-focused aesthetic solutions [2][6] Product and Market Expansion - SKINVIVE is described as the longest-lasting hydrating injectable on the market, providing deep hydration and smoothness with a single treatment [5][6] - The AA Signature™ approach, which includes SKINVIVE, aims to address diverse patient needs and improve skin quality, emphasizing a holistic treatment strategy [3][4] Consumer Insights - Research indicates that 94% of people desire to improve their facial skin quality, with deep hydration being a priority across all age groups [6][15] - Consumers are increasingly gravitating towards aesthetic treatments that yield natural-looking results, reflecting a desire for consistency and realistic outcomes rather than dramatic changes [6][15] Industry Events and Education - The Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai will feature discussions on the AA Signature™ approach and its integration into aesthetic practices [4][7] - A dedicated panel of renowned experts will explore the complexities of skin quality and its emotional connections, furthering the educational efforts of Allergan Aesthetics [7]